{"id":987314,"date":"2026-07-30T09:22:59","date_gmt":"2026-07-30T13:22:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/"},"modified":"2026-07-30T09:22:59","modified_gmt":"2026-07-30T13:22:59","slug":"capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/","title":{"rendered":"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation"},"content":{"rendered":"
\n

PHILADELPHIA, July 30, 2026 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR).<\/strong><\/a><\/p>\n

On July 27, 2026, the U.S. Food and Drug Administration (\u201cFDA\u201d) released briefing materials concerning Capricor\u2019s application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.<\/p>\n

\n According to Reuters<\/a>
\n ,<\/u> \u201cFDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics\u2019 cell therapy for a heart condition related to Duchenne muscular dystrophy . . ..\u201d Reuters reported that \u201c[t]he agency\u2019s staff said Capricor changed \u2060how it measured the main results after the therapy\u2019s late-stage trial ended, calculating arm-function performance \u200bas a percentage change instead of the original plan of analyzing scores in a 42-point \u200btest.\u201d<\/p>\n

On July 29, 2026, Stocktwits (via Yahoo Finance) reported<\/a> that “[s]hares of Capricor . . . are on track for a record weekly selloff after an [FDA] advisory panel voted 9-3 against Deramiocel . . ..”<\/p>\n

Stocktwits further reported that “[t]he FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee concluded on Wednesday that Capricor had not shown substantial evidence that Deramiocel effectively treats cardiomyopathy in DMD. Several panelists said the data was not convincing enough.”<\/p>\n

\n
\n On this news, shares of Capricor stock declined approximately 67%, closing at $6.57 per share on July 29, 2026. In premarket trading on July 30, 2026, the price of Capricor stock fell another 50% to approximately $3.00 per share.<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Capricor investors who have suffered financial losses<\/strong>
\n <\/a> are encouraged to complete Kehoe Law Firm’s<\/strong>Stockholder Information Request Form<\/strong><\/a> or contact Michael Yarnoff<\/strong>, Esq.<\/strong>, (215) 792-6676, Ext. 80<\/strong>4<\/strong>, <\/strong>myarnoff@kehoelawfirm.com<\/strong><\/a>, <\/strong>info@kehoelawfirm.com,<\/strong><\/a> for additional information and a free, no-obligation evaluation of potential legal claims.<\/p>\n

\n ABOUT KEHOE LAW FIRM, P.C.<\/strong>\n <\/p>\n

\n
\n Kehoe Law Firm, P.C.<\/strong>
\n <\/a> is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.<\/p>\n

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.<\/p>\n

This press release may constitute attorney advertising.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, July 30, 2026 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). On July 27, 2026, the U.S. Food and Drug Administration (\u201cFDA\u201d) released briefing materials concerning Capricor\u2019s application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. According to Reuters , \u201cFDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics\u2019 cell therapy for a heart condition related to Duchenne muscular dystrophy . . ..\u201d Reuters reported that \u201c[t]he agency\u2019s staff said Capricor changed \u2060how it measured the main results after the therapy\u2019s late-stage trial ended, calculating arm-function performance … <\/p>\n

Continue reading “CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-987314","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, July 30, 2026 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). On July 27, 2026, the U.S. Food and Drug Administration (\u201cFDA\u201d) released briefing materials concerning Capricor\u2019s application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. According to Reuters , \u201cFDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics\u2019 cell therapy for a heart condition related to Duchenne muscular dystrophy . . ..\u201d Reuters reported that \u201c[t]he agency\u2019s staff said Capricor changed \u2060how it measured the main results after the therapy\u2019s late-stage trial ended, calculating arm-function performance … Continue reading "CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T13:22:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation\",\"datePublished\":\"2026-07-30T13:22:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/\"},\"wordCount\":408,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/\",\"name\":\"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=\",\"datePublished\":\"2026-07-30T13:22:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/","og_locale":"en_US","og_type":"article","og_title":"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation - Market Newsdesk","og_description":"PHILADELPHIA, July 30, 2026 (GLOBE NEWSWIRE) — Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). On July 27, 2026, the U.S. Food and Drug Administration (\u201cFDA\u201d) released briefing materials concerning Capricor\u2019s application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. According to Reuters , \u201cFDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics\u2019 cell therapy for a heart condition related to Duchenne muscular dystrophy . . ..\u201d Reuters reported that \u201c[t]he agency\u2019s staff said Capricor changed \u2060how it measured the main results after the therapy\u2019s late-stage trial ended, calculating arm-function performance … Continue reading \"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-30T13:22:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation","datePublished":"2026-07-30T13:22:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/"},"wordCount":408,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/","name":"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=","datePublished":"2026-07-30T13:22:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwMDk1MSM3NzUxMjYzIzIxMjEyMjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-capricor-therapeutics-investors-encouraged-to-contact-kehoe-law-firm-p-c-regarding-securities-investigation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CAPR Investor Alert: Capricor Therapeutics Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Securities Investigation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/987314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=987314"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/987314\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=987314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=987314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=987314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}